{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:03Z","timestamp":1792896903002,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670148"],"award-info":[{"award-number":["81670148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bbmt.2020.01.012","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:32:53Z","timestamp":1579807973000},"page":"e128-e133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"Yanmin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.01.012_bib0001","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0002","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0003","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","article-title":"A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"T\u00f6rl\u00e9n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0004","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.leukres.2013.06.016","article-title":"Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation","volume":"37","author":"Zhu","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","article-title":"Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)","volume":"7","author":"Lai","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0006","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0007","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFN\u03b3R signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"Choi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0008","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1182\/blood-2011-06-363408","article-title":"Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen","volume":"118","author":"Betts","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0010","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0011","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0012","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","article-title":"The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia","volume":"24","author":"Schroeder","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0013","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0014","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0016","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0017","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood.V100.9.3128","article-title":"Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study","volume":"100","author":"Mohty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/trf.12859","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options","volume":"55","author":"Kim","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-018-3242-8","article-title":"Infections associated with ruxolitinib: study in the French Pharmacovigilance database","volume":"97","author":"Sylvine","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0021","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMc1716969","article-title":"Acute graft-versus-host disease","volume":"378","author":"Zeiser","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-017-0092-3","article-title":"Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis","volume":"6","author":"Sarmiento Maldonado","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0023","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.012_bib0024","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:39Z","timestamp":1761059499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120300239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1083879120300239"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy","name":"copyright","label":"Copyright"}]}}